Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]JOURNAL OF CROHNS & COLITISIF8.72021-12-2234OA
Life in lockdown: experiences of patients with IBD during COVID-19BMJ OPEN GASTROENTEROLOGYIF2.92020-11-1930OAAI
High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learningBMJ OPEN GASTROENTEROLOGYIF2.92020-11-137OAAI
MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial BarrierJOURNAL OF CROHNS & COLITISIF8.72019-10-188OAAI
High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methodsJOURNAL OF CROHNS & COLITISIF8.72019-01-251OAAI
Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseasesALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72017-04-172OAAI
microRNA23a Is Overexpressed in the Colonic Epithelium in Crohn's DiseaseGASTROENTEROLOGYIF25.12016-04-010PREAI
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72014-10-0647OAAI